To assess the specificity of this effect, the role of Stat6 in the response to rosiglitazone, a ligand of peroxisome proliferator-activated receptor γ (PPARγ), which has previously been reported to inhibit mammary cancer cell growth [40,41], was also examined. This evidence concerns the gene PPARG and breast cancer.